{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:27Z","timestamp":1790666547573,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older adults with metastatic triple-negative breast cancer (mTNBC) remain underrepresented in clinical trials. Although sacituzumab govitecan (SG) improved outcomes in the phase III ASCENT trial, real-world data in older populations remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, multinational study across 18 oncology centers in Central Europe, including patients with mTNBC treated with SG between August 2021 and May 2025. Patients were stratified by age at SG initiation: &amp;lt;65 vs \u226565\u2009years. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), treatment modifications, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 303 patients, 76 (25.1%) were aged \u226565\u2009years. Older patients had more comorbidities, more prior palliative treatment lines, and more frequent ECOG performance status \u22651. In unadjusted analyses, patients aged \u226565\u2009years had longer median OS (12.8 vs 10.9\u2009months; HR, 0.70; 95% CI, 0.49-0.99; P\u2009=\u20090.045) and PFS (5.4 vs 4.1\u2009months; HR, 0.73; 95% CI, 0.54-0.97; P\u2009=\u20090.031). ORR, DCR, treatment modifications, and grade \u22653 neutropenia were comparable between groups. In multivariable analyses, age was not independently associated with OS or PFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this selected real-world cohort, patients aged \u226565\u2009years who received SG had outcomes at least comparable to those of younger patients, without an apparent excess severe toxicity. Survival differences were likely influenced by baseline disease characteristics and patient selection rather than chronological age alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag281","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T11:33:57Z","timestamp":1784460837000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-7923","authenticated-orcid":false,"given":"Aleksandra","family":"Konieczna","sequence":"first","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology Department of Breast Cancer and Reconstructive Surgery, , Warsaw 02-781,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Pieni\u0105\u017cek","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University, Lower Silesian Comprehensive Cancer Center Department of Oncology, Breast Unit Clinical Oncology Day Care Department, , Wroclaw 53-413,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"\u017bubrowska","sequence":"additional","affiliation":[{"name":"Holy Cross Cancer Center Department of Clinical Oncology, , Kielce 25-734,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-7067","authenticated-orcid":false,"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch Breast Cancer Center, , Gliwice 44-102,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Soumarov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University, University Hospital Kralovske Vinohrady Department of Oncology, Third Faculty of Medicine, , Prague 100 34,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Hol\u00e1nek","sequence":"additional","affiliation":[{"name":"Masaryk Memorial Cancer Institute, and Faculty of Medicine, Masaryk University Department of Comprehensive Cancer Care, , Brno 656 53,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[{"name":"Palacky University and University Hospital Department of Oncology, Faculty of Medicine and Dentistry, , Olomouc 779 00,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"M\u0142odzi\u0144ska","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology Department of Breast Cancer and Reconstructive Surgery, , Warsaw 02-781,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Winsko-Szcz\u0119snowicz","sequence":"additional","affiliation":[{"name":"M. Sklodowska-Curie Bialystok Oncology Center Department of Clinical Oncology, , Bialystok 15-027,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Lisik-Habib","sequence":"additional","affiliation":[{"name":"Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology Department of Proliferative Diseases, , Lodz 95-513,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"P\u0119kala","sequence":"additional","affiliation":[{"name":"Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology Department of Proliferative Diseases, , Lodz 95-513,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Krej\u010d\u00ed","sequence":"additional","affiliation":[{"name":"Charles University in Prague, and Bulovka University Hospital Department of Oncology, First Faculty of Medicine, , Prague 180 81,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4264-3285","authenticated-orcid":false,"given":"Jan","family":"\u0160ustr","sequence":"additional","affiliation":[{"name":"Faculty of Medicine in Pilsen, Charles University, and University Hospital Pilsen Department of Oncology and Radiotherapy, , Plzen 301 00,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Kol\u00e1\u0159ov\u00e1","sequence":"additional","affiliation":[{"name":"Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University Department of Oncology and Radiotherapy, , Hradec Kralove 500 05,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[{"name":"Pomeranian Hospitals Department of Clinical Oncology with BCU, , Gdynia 81-519,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Szymanik-Resko","sequence":"additional","affiliation":[{"name":"Pomeranian Hospitals Department of Clinical Oncology with BCU, , Gdynia 81-519,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Ciszewski","sequence":"additional","affiliation":[{"name":"Medical University of Lublin Department of Metabolic Diseases and Immuno-oncology, , Lublin 20-080,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Ru\u0161inov\u00e1","sequence":"additional","affiliation":[{"name":"Stefan Kukura Hospital Department of Oncology, , Michalovce 071 01, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogumi\u0142a","family":"Czartoryska-Ar\u0142ukowicz","sequence":"additional","affiliation":[{"name":"M. Sklodowska-Curie Bialystok Oncology Center Department of Clinical Oncology, , Bialystok 15-027,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2014-993X","authenticated-orcid":false,"given":"Aleksandra","family":"\u0141acko","sequence":"additional","affiliation":[{"name":"Holy Cross Cancer Center Department of Clinical Oncology, , Kielce 25-734,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2642-9724","authenticated-orcid":false,"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch Breast Cancer Center, , Gliwice 44-102,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kubeczko","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch Breast Cancer Center, , Gliwice 44-102,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pacholczak-Madej","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch Department of Gynecological Oncology, , Krakow 31-115,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Smok-Kalwat","sequence":"additional","affiliation":[{"name":"Holy Cross Cancer Center Department of Clinical Oncology, , Kielce 25-734,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Nowecki","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology Department of Breast Cancer and Reconstructive Surgery, , Warsaw 02-781,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Biel\u010dikov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University, and General University Hospital Department of Oncology, First Faculty of Medicine, , Prague 128 08,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Malej\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"National Cancer Institute II. Oncology Clinic of LFUK, , Bratislava 833 10, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch Department of Clinical Oncology, , Krakow 31-115,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026081219363764200_oyag281-B1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2026081219363764200_oyag281-B2","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.3390\/jcm11206021","article-title":"Current therapeutic strategies for metastatic triple-negative breast cancer: from pharmacists\u2019 perspective","volume":"11","author":"Li","year":"2022","journal-title":"J Clin Med"},{"key":"2026081219363764200_oyag281-B3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081219363764200_oyag281-B4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/cancers16061087","article-title":"Retrospective observational study to determine the epidemiology and treatment patterns of patients with triple-negative breast cancer","volume":"16","author":"Rosi\u0144ska","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026081219363764200_oyag281-B5","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026081219363764200_oyag281-B6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10549-010-0898-8","article-title":"Breast cancer in elderly compared to younger patients in The Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients","volume":"124","author":"Bastiaannet","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2026081219363764200_oyag281-B7","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1200\/JCO.2006.10.4208","article-title":"Older female cancer patients: importance, causes, and consequences of undertreatment","volume":"25","author":"Bouchardy","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026081219363764200_oyag281-B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11912-015-0475-8","article-title":"Treatment of breast cancer in the elderly","volume":"17","author":"Freedman","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"2026081219363764200_oyag281-B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","article-title":"Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"10","author":"Hurvitz","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"2026081219363764200_oyag281-B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.6004\/jnccn.2021.7055","article-title":"Representation and outcomes of older adults in practice-changing oncology trials in the era of novel therapies: a guideline appraisal","volume":"20","author":"Chow","year":"2022","journal-title":"J Natl Compreh Cancer Netw"},{"key":"2026081219363764200_oyag281-B11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","article-title":"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States","volume":"208","author":"Kalinsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2026081219363764200_oyag281-B12","doi-asserted-by":"publisher","first-page":"e305-16","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026081219363764200_oyag281-B13","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/S1470-2045(4)70383-7","article-title":"Management of elderly patients with breast cancer: updated recommendations of the international society of geriatric oncology (SIOG) and European society of breast cancer specialists (EUSOMA)","volume":"13","author":"Biganzoli","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026081219363764200_oyag281-B14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jgo.2018.12.008","article-title":"SIOG guidelines-essential for good clinical practice in geriatric oncology","volume":"10","author":"Dubianski","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"2026081219363764200_oyag281-B15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026081219363764200_oyag281-B16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-020-05727-x","article-title":"A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns","volume":"182","author":"Tzikas","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026081219363764200_oyag281-B17","doi-asserted-by":"publisher","first-page":"104428","DOI":"10.1016\/j.breast.2025.104428","article-title":"Antibody-drug conjugates in elderly patients with breast cancer","volume":"80","author":"Bonotto","year":"2025","journal-title":"Breast"},{"key":"2026081219363764200_oyag281-B18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2021.39.15_suppl.1011","article-title":"Outcomes in patients (pts) aged \u226565 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)","volume":"39","author":"Kalinsky","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026081219363764200_oyag281-B19","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","article-title":"Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom","volume":"130","author":"Hanna","year":"2024","journal-title":"Br J Cancer"},{"key":"2026081219363764200_oyag281-B20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/OP.24.00242","article-title":"Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"21","author":"Alaklabi","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026081219363764200_oyag281-B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-025-00736-9","article-title":"Real-world outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases","volume":"11","author":"Grinda","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"2026081219363764200_oyag281-B22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.3390\/biomedicines13092059","article-title":"Effectiveness and safety of sacituzumab govitecan in real-world clinical practice in patients with metastatic triple-negative and HR+\/HER2-negative breast cancer","volume":"13","author":"Lago-Ballester","year":"2025","journal-title":"Biomedicines"},{"key":"2026081219363764200_oyag281-B23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40487-024-00307-1","article-title":"Sacituzumab govitecan for second and subsequent line palliative treatment of patients with triple-negative breast cancer: a polish real-world multicenter cohort study","volume":"12","author":"P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","journal-title":"Oncol Ther"},{"key":"2026081219363764200_oyag281-B24","doi-asserted-by":"publisher","first-page":"S419","DOI":"10.1016\/j.annonc.2025.08.988","article-title":"566P effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe","volume":"36","year":"2025","journal-title":"Ann Oncol."},{"key":"2026081219363764200_oyag281-B25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/amj-23-188","article-title":"A narrative review of the efficacy and safety FDA-approved antibody-drug conjugates in older patients","volume":"9","author":"Hsu","year":"2024","journal-title":"AME Med J"},{"key":"2026081219363764200_oyag281-B26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12957-024-03424-3","article-title":"Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis","volume":"22","author":"Lin","year":"2024","journal-title":"World J Surg Oncol"},{"key":"2026081219363764200_oyag281-B27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jfma.2021.04.028","article-title":"Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: age as a significant treatment effect-modifier","volume":"121","author":"Chung","year":"2022","journal-title":"J Formosan Med Assoc"},{"key":"2026081219363764200_oyag281-B28","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1200\/JCO.2013.49.6125","article-title":"End points and trial design in geriatric oncology research: a joint european organisation for research and treatment of cancer-alliance for clinical trials in oncology-international society of geriatric oncology position article","volume":"31","author":"Wildiers","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026081219363764200_oyag281-B29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10549-019-05442-2","article-title":"Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications","volume":"179","author":"Allott","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026081219363764200_oyag281-B30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Use of comprehensive geriatric assessment in older cancer patients","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026081219363764200_oyag281-B31","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026081219363764200_oyag281-B32","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026081219363764200_oyag281-B33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jgo.2020.07.003","article-title":"Implementation of geriatric assessment in oncology settings: a systematic realist review","volume":"12","author":"McKenzie","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"2026081219363764200_oyag281-B34","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1634\/theoncologist.2014-0184","article-title":"Age-specific changes in intrinsic breast cancer subtypes: a focus on older women","volume":"19","author":"Jenkins","year":"2014","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag281\/69636348\/oyag281.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag281\/69636348\/oyag281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag281\/69636348\/oyag281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:36:44Z","timestamp":1786577804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag281\/8738595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag281","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,20]]},"article-number":"oyag281"}}